Insider Buying: Larimar Therapeutics (NASDAQ:LRMR) Director Acquires $186,900.00 in Stock

Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) Director Thomas Hamilton purchased 70,000 shares of the stock in a transaction that occurred on Thursday, November 12th. The shares were acquired at an average cost of $2.67 per share, for a total transaction of $186,900.00. Following the completion of the transaction, the director owned 70,000 shares of the company’s stock, valued at $186,900. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Larimar Therapeutics Price Performance

Larimar Therapeutics stock traded up $0.32 during midday trading on Friday, hitting $3.02. The company’s stock had a trading volume of 2,531,459 shares, compared to its average volume of 1,257,255. The company has a market cap of $313.72 million, a price-to-earnings ratio of -1.55 and a beta of 0.73. Larimar Therapeutics, Inc. has a 1-year low of $1.91 and a 1-year high of $6.42. The company has a 50-day moving average price of $2.93 and a two-hundred day moving average price of $3.76.

Wall Street Analyst Weigh In

Several research analysts have recently commented on LRMR shares. Wedbush reaffirmed an “outperform” rating on shares of Larimar Therapeutics in a report on Tuesday. Wall Street Zen downgraded shares of Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Thursday, October 15th. Finally, Leerink Partners began coverage on Larimar Therapeutics in a research report on Monday, September 14th. They set an “outperform” rating and a $13.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $10.33.

Get Our Latest Stock Analysis on LRMR

Key Larimar Therapeutics News

Here’s some of the latest news about LRMR:

  • Positive Sentiment: CEO Carole Ben-Maimon, CFO Michael Celano, COO John B. Jr. Harlow, insider Gopi Shankar, and directors Frank Thomas and Joseph Truitt together purchased 52,810 shares for roughly $195,000. Director Thomas Hamilton separately bought 70,000 shares for $186,900. Insider purchase report Hamilton SEC filing
  • Neutral Sentiment: The supplied coverage also notes H.C. Wainwright maintained a Buy rating; no rating change or fresh price-moving catalyst was reported. Analyst rating report

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Blue Owl Capital Holdings LP lifted its position in Larimar Therapeutics by 0.3% during the third quarter. Blue Owl Capital Holdings LP now owns 9,923,904 shares of the company’s stock worth $31,707,000 after purchasing an additional 32,147 shares during the period. BlackRock Inc. bought a new position in Larimar Therapeutics in the 2nd quarter valued at about $17,318,000. Marshall Wace LLP increased its holdings in Larimar Therapeutics by 9.1% in the 3rd quarter. Marshall Wace LLP now owns 2,195,954 shares of the company’s stock valued at $7,005,000 after buying an additional 183,496 shares during the period. AIGH Capital Management LLC bought a new position in Larimar Therapeutics in the 3rd quarter valued at about $5,911,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Larimar Therapeutics by 143.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 798,462 shares of the company’s stock valued at $3,592,000 after buying an additional 470,968 shares in the last quarter. Institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

(Get Free Report)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

Recommended Stories

Insider Buying and Selling by Quarter for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.